Medicare Enrolled
Dr. Madhura Hanmantgad, MD
Hematology & Oncology · Hawthorne, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hanmantgad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hanmantgad?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hanmantgad
Dr. Madhura Hanmantgad is a hematology & oncology specialist in Hawthorne, NY, with 11 years of NPI registration. Based on federal Medicare data, Dr. Hanmantgad performed 1,758 Medicare services across 725 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hanmantgad received a total of $4,854 from 46 pharmaceutical and/or device companies across 231 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hanmantgad is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ Top 33% volume in NY
$4,854 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,758
Medicare services
Top 33% in NY for hematology & oncology
725
Unique beneficiaries
$57
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~160 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
504 | $8 | $28 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
459 | $103 | $368 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
312 | $68 | $259 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
239 | $8 | $12 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
40 | $98 | $381 |
| New patient office visit, complex (60-74 min) | 35 | $184 | $626 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
34 | $21 | $110 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
32 | $150 | $512 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
32 | $104 | $376 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
30 | $63 | $198 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $125 | $504 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
12 | $143 | $553 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$4,854
Total received (2022-2024)
Avg $1,618/year across 3 years
Top 35% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
231
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,854 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,564
2023
$2,128
2022
$162
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$361
Novartis Pharmaceuticals Corporation
$182
Janssen Biotech, Inc.
$178
E.R. Squibb & Sons, L.L.C.
$170
AstraZeneca Pharmaceuticals LP
$166
Rigel Pharmaceuticals, Inc.
$138
Daiichi Sankyo Inc.
$106
Mirati Therapeutics, Inc.
$104
JAZZ PHARMACEUTICALS INC.
$90
Exelixis Inc.
$86
Genentech USA, Inc.
$80
Incyte Corporation
$77
PFIZER INC.
$76
ARRAY BIOPHARMA INC
$68
Bayer Healthcare Pharmaceuticals Inc.
$63
BeiGene USA, Inc.
$57
SOBI, INC
$54
Merck Sharp & Dohme LLC
$51
Regeneron Healthcare Solutions, Inc.
$50
Gilead Sciences, Inc.
$49
Aveo Pharmaceuticals, Inc.
$44
PUMA BIOTECHNOLOGY, INC.
$35
Myriad Genetic Laboratories, Inc.
$32
GlaxoSmithKline, LLC.
$31
Celgene Corporation
$28
Alexion Pharmaceuticals, Inc.
$26
Lilly USA, LLC
$23
Ipsen Biopharmaceuticals, Inc
$22
Coherus Biosciences Inc.
$22
PROGENICS PHARMACEUTICALS, INC.
$22
EMD Serono, Inc.
$20
Eisai Inc.
$18
SERVIER PHARMACEUTICALS LLC
$17
PharmaEssentia USA Corporation
$16
Top 3 companies account for 28.1% of 2024 payments
All-time payments by company (2022-2024) ›
ABBVIE INC.
$382
Novartis Pharmaceuticals Corporation
$349
Celgene Corporation
$294
Janssen Biotech, Inc.
$265
E.R. Squibb & Sons, L.L.C.
$235
AstraZeneca Pharmaceuticals LP
$210
Rigel Pharmaceuticals, Inc.
$209
Mirati Therapeutics, Inc.
$196
PFIZER INC.
$188
Gilead Sciences, Inc.
$162
Merck Sharp & Dohme LLC
$129
Incyte Corporation
$129
Genentech USA, Inc.
$124
Pharmacyclics LLC, An AbbVie Company
$116
Daiichi Sankyo Inc.
$106
Exelixis Inc.
$100
Lilly USA, LLC
$99
Coherus Biosciences Inc.
$97
SOBI, INC
$93
JAZZ PHARMACEUTICALS INC.
$90
ARRAY BIOPHARMA INC
$86
Bayer Healthcare Pharmaceuticals Inc.
$84
Seagen Inc.
$83
Takeda Pharmaceuticals U.S.A., Inc.
$77
Astellas Pharma US Inc
$74
Eisai Inc.
$74
Regeneron Healthcare Solutions, Inc.
$73
GENZYME CORPORATION
$71
Myriad Genetic Laboratories, Inc.
$62
BeiGene USA, Inc.
$57
Ipsen Biopharmaceuticals, Inc
$56
Amgen Inc.
$55
Aveo Pharmaceuticals, Inc.
$44
PharmaEssentia USA Corporation
$40
SERVIER PHARMACEUTICALS LLC
$40
EMD Serono, Inc.
$39
Karyopharm Therapeutics Inc.
$37
PUMA BIOTECHNOLOGY, INC.
$35
Jazz Pharmaceuticals Inc.
$34
GlaxoSmithKline, LLC.
$31
Alexion Pharmaceuticals, Inc.
$26
Puma Biotechnology, Inc.
$22
PROGENICS PHARMACEUTICALS, INC.
$22
Stemline Therapeutics Inc.
$21
Progenics Pharmaceuticals, Inc.
$20
MorphoSys, US Inc.
$15
Top 3 companies account for 21.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · Alecensa · BAVENCIO · BESREMI · BOSULIF · BRUKINSA · CABOMETYX · CALQUENCE · CARVYKTI · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Enhertu · FOTIVDA · Fabhalta · GAMIFANT · IMBRUVICA · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LORBRENA · LUMAKRAS · Lenvima · MONJUVI · MYRISK · NINLARO · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · Onivyde · Orserdu · PRECISETUMOR · PROMACTA · PYLARIFY · Padcev · Perjeta · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Rezlidhia · SCEMBLIX · Stivarga · TAGRISSO · TASIGNA · TECVAYLI · TUKYSA · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VONVENDI · Venclexta · Voranigo · XPOVIO · XTANDI · Xospata · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
450
Per 100K population
45.1
County median income
$118,411
Nearest hospital
WESTCHESTER MEDICAL CENTER
1.4 mi
1.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Hanmantgad is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Hanmantgad experienced with complete blood count (cbc) with differential?
Based on Medicare claims data, Dr. Hanmantgad performed 504 complete blood count (cbc) with differential services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hanmantgad receive payments from pharmaceutical companies?
Yes. Dr. Hanmantgad received a total of $4,854 from 46 companies across 231 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hanmantgad's costs compare to other hematology & oncology specialists in Hawthorne?
Dr. Hanmantgad's average Medicare payment per service is $57. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hanmantgad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Hawthorne
Browse hematology & oncology specialists in Hawthorne ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology